At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GMDA Gamida Cell Ltd.
Delisted 12-20 16:00:00 EST
0.0327
+0.0000
0.00%
High0.0327
Low0.0327
Vol0.00
Open0.0327
D1 Closing0.0327
Amplitude0.00%
Mkt Cap5.04M
Tradable Cap4.64M
Total Shares154.05M
T/O0.00
T/O Rate0.00%
Tradable Shares142.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.